drugset
drugset / Trial / NCT04827472

Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers

NCT04827472 ↗

Phase 1 Unknown 36 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

The safety/tolerability and pharmacokinetic properties of DWJ1521 are evaluated after single intravenous administration of DWJ1521 in healthy adults. The safety/tolerability and pharmacokinetic properties of DWJ1521 single intravenous administration and DWP14012 single oral administration in healthy adults are compared.

Timeline

Start
2021-01-20
Primary completion
2021-06-30
Completion
2021-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule — Oral
Subject DWJ1521 Unknown — Intravenous

Indications

No indication recorded.